Optometrists best placed to screen population
Although almost a third of patients referred by optometrists do not have glaucoma, optometrists are still best placed to screen the UK population for glaucoma, according to Dr Aye and colleagues from Northampton General Hospital, UK.
Although almost a third of patients referred by optometrists do not have glaucoma, optometrists are still best placed to screen the UK population for glaucoma, according to Dr Aye and colleagues from Northampton General Hospital, UK.
A study was conducted to review the glaucoma data provided by optometrists on referral forms. A total of 78 referrals were received over a five-month period. The most common reasons for referral were elevated IOP (59%), optic disc abnormalities (45%), visual field defects (14%) and other abnormalities (12%).
A total of 68% of forms were incomplete, missing vital data. Of the IOP measurements, 38% were within 2 mmHg of IOP obtained with Goldmann tonometry and 34% of pneumatonometry readings differed by more than 5 mmHg with that obtained by applanation tonometry. Twenty-seven percent of patients were found not to have glaucoma and were discharged, while 26% of patients were started on treatment.
According to the investigators, despite varying IOP measurements, optometrists are still best placed to screen the UK population for glaucoma.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
August 5th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
